The UAE pathway after the EDE transition: local agents, manufacturer and product registration, the verification route, dossiers, pricing and timelines.
Drug registration in the United Arab Emirates has changed authority: the Emirates Drug Establishment (EDE), created under Federal Decree-Law No. 38 of 2024, has taken over the federal regulation of medicines from the Ministry of Health and Prevention (MOHAP), absorbing the registration, licensing and pharmacovigilance services that pharmaceutical companies previously ran through MOHAP's drug department. The framework a company works through in 2026 is recognizably the one MOHAP built (company registration before product registration, a CTD dossier, a local authorized agent, pricing review), while the counterpart authority, the portal, several of the rules and the enforcement posture are now EDE's.
This guide covers the UAE pathway as it now runs: who regulates what after the transition, product classification, the local agent requirement and the February 2026 multiple-agents reform, manufacturer and product registration, the standard and verification pathways, the dossier, pricing, timelines, post-approval obligations including serialization and pharmacovigilance, and where the UAE sits in the wider GCC picture. It is written for pharmaceutical companies planning a UAE entry and for the regulatory teams preparing the submissions, and it is the UAE companion to our drug registration in India guide.
1. The regulatory landscape after the EDE transition
Federal Decree-Law No. 38 of 2024 established the EDE as the federal authority for medical products: pharmaceuticals, biologicals, complementary and herbal medicines, and defined classes of medical devices and medicated cosmetics. Through 2025 and into 2026 the registration, establishment licensing, variation, advertising approval and pharmacovigilance services moved from MOHAP to the EDE, and companies operating under MOHAP-era approvals were given a statutory grace period, running to early January 2026, to align with the new law.
Registration is federal: a product registered with the EDE can be marketed across all seven emirates; the emirate health authorities, the Department of Health Abu Dhabi (DoH) and the Dubai Health Authority (DHA) among them, no longer run parallel product registrations and concentrate on licensing healthcare facilities and professionals, formulary decisions and procurement within their systems, where proof of EDE registration is what they ask for. MOHAP retains community and compounding pharmacy licensing and certain narcotics controls. The EDE carries inspection and enforcement powers under the law: unannounced inspections, product seizure, license suspension and cancellation, with defined violations for circulating unregistered products, manufacturing without valid GMP certification and advertising without approval.
For a company entering now, applications and correspondence run through the EDE and its digital services, MOHAP-era registrations and pending files carried over and are now maintained under EDE rules, and guidance issued before the transition is checked against the new law before it is relied on.
2. Who regulates what in the UAE
| Function | Authority |
|---|---|
| Drug, biological and complementary medicine registration | EDE (federal) |
| Manufacturer and pharmaceutical establishment licensing | EDE |
| Pricing of registered medicines | EDE pricing review within registration |
| Pharmacovigilance and safety reporting | EDE (centralized) |
| Advertising approval for medical products | EDE |
| Healthcare facility and professional licensing | Emirate authorities (DoH Abu Dhabi, DHA Dubai, and counterparts) |
| Formulary and procurement within emirate health systems | Emirate authorities, on proof of EDE registration |
| Free zone establishment licensing (for example Dubai Healthcare City) | Free zone regulator, with product registration still federal through the EDE |
| Community and compounding pharmacy licensing, certain narcotics controls | Retained by MOHAP |
3. Product classification
The pathway and evidence expectation follow the product category: a new (innovative) drug, a generic, a biological or biosimilar, an over-the-counter medicine, a complementary, herbal or health supplement product, or a controlled substance with its additional permissions. Classification is settled first because it decides the dossier content, the review route, the pricing treatment and, for borderline consumer products, whether the product is regulated as a medicine at all. A product marketed as a supplement elsewhere can classify as a medicine in the UAE on its ingredients or claims, the reverse also occurs, and re-classification after filing restarts the work.
4. The local authorized agent, and the end of the single-agent model
A foreign manufacturer works through a UAE-based authorized agent: a licensed pharmaceutical establishment, typically a medical warehouse, drug store or scientific/marketing office, which files and maintains the registration, holds the registration relationship, submits the applications, and carries the post-market obligations, importation and pharmacovigilance duties on the ground. The agent's own EDE establishment license, and its named responsible pharmacist and pharmacovigilance arrangements, are prerequisites the product application inherits.
The single-agent era ended in February 2026, when the EDE activated a mechanism allowing manufacturers to register multiple authorized agents for the same product, replacing the exclusive-distributor model that had governed the market for decades. For market entrants this changes the commercial architecture: agency agreements, territory and supply arrangements can now be structured across more than one agent, and the registration strategy is set together with the distribution strategy.
5. Registering the manufacturer and the product
The sequence runs in two stages. The manufacturing site and the marketing authorization holder are registered with the EDE first: corporate documents, the manufacturing license from the country of origin, GMP certification from a recognized authority with the inspection history behind it, and the site's product range. Product applications follow, filed per product against the registered site, through the EDE's electronic system.
Company registration is where foreign manufacturers most often lose unplanned time, because the document set runs through legalization: certificates issued in the origin country typically need notarization and attestation through to the UAE embassy chain, and an expired or improperly legalized document stops the file. The product stage then carries the dossier of section 7, with EDE technical review, rounds of queries, and, where the category requires it, sample analysis, before the registration certificate and the price are issued together. Our UAE regulatory submissions service covers both stages, from the agent-stage document set to the product file.
6. Standard and verification pathways
The standard pathway is the full technical review of the dossier. Alongside it, the UAE operates verification and reliance-based review for products already approved by recognized reference authorities, the European Medicines Agency, the US FDA, the UK MHRA and Japan's PMDA among them, in which the EDE leans on the reference assessment and verifies the UAE-specific elements, the local labeling, the agent, the pricing, the GCC-relevant stability data, on a shorter clock. Which products qualify, and what the abbreviated review covers, follows the EDE's current criteria, and the pathway is confirmed for the specific product before the submission strategy is fixed, because the two routes differ in documents, sequencing and timeline. The same logic that India applies through its reference-country waiver provisions, covered in our India registration guide, operates here through reliance on the reference assessment itself.
7. UAE drug registration dossier requirements
The submission is a CTD-format dossier, and the UAE-specific work concentrates in Module 1 and the quality module:
- Administrative and regional information: application forms, the agent's authorization and establishment license, the Certificate of Pharmaceutical Product (CPP) or reference approvals, GMP certificates, and the pricing application
- Labeling: artwork and package leaflet in Arabic and English to the EDE's bilingual requirements, consistent with the approved reference text where a reliance route is used
- Quality: full chemistry, manufacturing and controls information, with long-term stability generated under the hot-zone conditions the GCC stability framework requires, a recurring gap for dossiers built only for temperate-zone filings
- Nonclinical and clinical: the modules scale with the category, a full package for an innovative product, bioequivalence against the UAE-acceptable reference product for a generic, and the comparability package for a biosimilar
Before filing, the dossier is checked for cross-module consistency: the indication, strength and shelf life claimed in Module 1 match the evidence and the stability data, the artwork matches the approved text, and the agent and site details match the establishment registrations, because each mismatch returns as a query that stops the clock.
8. Pricing review
Price approval is part of registration, and the registered price is a condition of sale. The review references the product's pricing in the country of origin and a basket of other markets, together with the GCC pricing environment, and the outcome interacts with launch sequencing across the Gulf: a price set in one GCC market becomes a reference for the others, so the regional pricing strategy is set before the first Gulf submission. Price maintenance continues after approval, with re-registration and periodic price review under the EDE's rules.
9. UAE drug registration timeline
Published figures for the UAE put a standard new generic registration in the range of nine to eighteen months end to end, with the verification pathway shorter, and the company-registration stage in front of it adding its own weeks to months depending on legalization. The review clock stops during queries, and the practical timeline is planned stage by stage: agent and establishment registration, dossier build including any GCC-zone stability still running, EDE review with query rounds, then pricing and certificate issuance. Fees and processing targets are set by the EDE and revised; the current figures are checked on the EDE's official service pages at planning time.
10. Post-approval obligations
- Pharmacovigilance. Safety oversight is centralized under the EDE, with pharmacovigilance officer requirements at the establishment level, expedited reporting of serious adverse events, and periodic safety update reports on the required cadence. EvySaif's pharmacovigilance writing and aggregate safety reports services cover the documentation side.
- Serialization. The UAE operates the Tatmeen track-and-trace platform, introduced under the 2021 pharmaceutical traceability decree and live since December 2022: products carry GS1 DataMatrix serialization, supply chain movements are reported through the system, and linking a product to the platform is a legal precondition for importing or trading it. The agent and supply chain are set up for it before launch.
- Variations and renewals. Changes to the product, site, artwork or agent are filed as variations under the EDE's classification, and registrations are renewed on their cycle; a change implemented without the corresponding filing puts the registration at risk.
- Advertising. Promotion of medical products requires EDE approval, with public advertising of controlled categories prohibited.
11. The UAE inside the GCC
The UAE market is usually one leg of a Gulf strategy. The Gulf Cooperation Council operates a centralized registration track alongside the national routes, GCC-registered sites and products gaining recognition across member states, and the GCC registration decision, central versus national-by-national, is taken on the target markets, the product category and the pricing plan. Saudi Arabia, the largest Gulf market, runs its own full national system under the SFDA, and the SFDA and EDE outcomes reference each other commercially through pricing even where the regulatory files are separate. A dossier built once to CTD with GCC-zone stability, bilingual labeling and a coherent regional pricing position serves all of these routes; our regulatory writing team builds to that standard, and regulatory strategy consulting covers the sequencing.
12. Common causes of delay
- Legalization underestimated. Origin-country certificates arriving unattested, expired or inconsistent with the application details, stopping the company-registration stage.
- Classification assumed. A supplement-style product filed on the wrong side of the medicine line and returned for the other route.
- Temperate-zone stability. A dossier without long-term data under the GCC's hot-zone conditions, discovered at technical review with the study still months from readout.
- Labeling non-compliance. Artwork missing the bilingual requirements or diverging from the reference text on a reliance route.
- Agent structure unsettled. Registration begun before the agency agreement, and now the multiple-agent structure, is commercially settled, so the file waits on the business.
- Pricing filed as an afterthought. A UAE price proposed without the GCC reference consequences worked through, forcing a late correction that other markets then inherit.
- Pre-transition assumptions. Requirements, forms or contacts carried over from MOHAP-era experience without checking the EDE's current rules.
13. Frequently asked questions
The Emirates Drug Establishment (EDE), the federal authority created under Federal Decree-Law No. 38 of 2024, which took over drug registration, establishment licensing, pricing, pharmacovigilance and advertising approval from MOHAP.
MOHAP's drug registration, licensing, pricing and pharmacovigilance services transferred to the EDE through 2025 and early 2026. MOHAP-era registrations carried over and are maintained under the EDE's rules, and new applications are filed with the EDE.
No. EDE registration is federal and covers all seven emirates. Emirate authorities license facilities and professionals and manage their formularies, and they rely on the EDE registration for products.
Registration is filed through a UAE-based authorized agent, a licensed pharmaceutical establishment, which holds the application and the post-market obligations. Since February 2026 a manufacturer can register more than one authorized agent for the same product.
An abbreviated, reliance-based review for products already approved by recognized reference authorities such as the EMA, US FDA, UK MHRA and PMDA, in which the EDE relies on the reference assessment and reviews the UAE-specific elements on a shorter timeline.
Published figures put a standard new generic at roughly nine to eighteen months, with the verification route shorter and company registration adding time in front. The clock stops during queries, so dossier completeness drives the real number.
Arabic and English, to the EDE's bilingual labeling requirements, across artwork and the package leaflet.
The Certificate of Pharmaceutical Product, or equivalent evidence of the reference approval, sits in Module 1 for imported products; on reliance routes the reference approvals also anchor the review itself.
Long-term stability generated under the GCC's hot climatic zone conditions for the proposed shelf life, in addition to accelerated data; temperate-zone data alone are a recurring rejection point.
The UAE's national track-and-trace platform for medical products: registered products are serialized to GS1 standards and their supply chain movements reported through the system.
The GCC centralized track and the national routes coexist, and the choice is strategic: target markets, category, timelines and pricing. Many companies run national submissions in the priority markets, the UAE and Saudi Arabia first among them, with the GCC route considered for the wider region.
14. Work with EvySaif on your UAE registration
EvySaif is a clinician-led regulatory, drug clinical development and medical writing consultancy in Pune, India, working with pharmaceutical, biotech and device companies across India, the Middle East and Europe, with UAE submissions as an established service line alongside the GCC and SFDA routes. The work runs end to end: classification and pathway confirmation including the verification route, the agent-stage document set with its legalization checklist, the CTD dossier with the Module 1, labeling and GCC-zone stability elements the UAE review turns on, query responses, and the post-approval cycle of variations, renewals and safety reporting.
The engagement starts with the product and the Gulf plan, because the pathway, agent-structure and price decisions are rarely well made for one market alone. We commit to a correct classification, a complete and internally consistent dossier, and a submission strategy that treats the UAE as part of the regional sequence. If a UAE or wider Gulf registration is on your roadmap, contact EvySaif with the product, its approval history and the target markets, and we will return the pathway, the document gaps and the sequence before any dossier work starts.
Last reviewed: September 2026. This article is general information for education; verify requirements and methods against current official sources for any specific project.